Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders (2010 - 2026)

Jazz Pharmaceuticals' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at $293.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 418.59% year-over-year to $293.1 million; the TTM figure through Mar 2026 stood at $29.7 million (down 93.86% YoY), while the FY2025 annual figure was -$355.5 million, down 163.27% from the prior year.
• Net Income towards Common Stockholders was $293.1 million for Q1 2026 at Jazz Pharmaceuticals, up from $203.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $293.1 million in Q1 2026 to a low of -$718.4 million in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged $41.4 million across 5 years, with a median of $94.6 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 641.8% in 2022, then soared 1109.01% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$240.0 million in 2022, then soared by 139.44% to $94.6 million in 2023, then jumped by 101.96% to $191.1 million in 2024, then rose by 6.46% to $203.5 million in 2025, then surged by 44.05% to $293.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $293.1 million (Q1 2026), $203.5 million (Q4 2025), and $251.5 million (Q3 2025), per Business Quant data.